- Home
- SPCB vs IMMX Comparison
SPCB vs IMMX Comparison
Compare SPCB & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCB
- IMMX
- Stock Information
- Founded
- SPCB 1988
- IMMX 2014
- Country
- SPCB Israel
- IMMX United States
- Employees
- SPCB N/A
- IMMX N/A
- Industry
- SPCB Semiconductors
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- SPCB Technology
- IMMX Health Care
- Exchange
- SPCB Nasdaq
- IMMX Nasdaq
- Market Cap
- SPCB 53.3M
- IMMX 61.1M
- IPO Year
- SPCB N/A
- IMMX 2021
- Fundamental
- Price
- SPCB $10.55
- IMMX $2.13
- Analyst Decision
- SPCB Strong Buy
- IMMX Strong Buy
- Analyst Count
- SPCB 1
- IMMX 1
- Target Price
- SPCB $18.00
- IMMX $7.00
- AVG Volume (30 Days)
- SPCB 190.1K
- IMMX 261.4K
- Earning Date
- SPCB 08-14-2025
- IMMX 08-11-2025
- Dividend Yield
- SPCB N/A
- IMMX N/A
- EPS Growth
- SPCB N/A
- IMMX N/A
- EPS
- SPCB 1.89
- IMMX N/A
- Revenue
- SPCB $27,831,000.00
- IMMX N/A
- Revenue This Year
- SPCB $2.73
- IMMX N/A
- Revenue Next Year
- SPCB $22.87
- IMMX N/A
- P/E Ratio
- SPCB $5.44
- IMMX N/A
- Revenue Growth
- SPCB 2.90
- IMMX N/A
- 52 Week Low
- SPCB $2.55
- IMMX $1.26
- 52 Week High
- SPCB $18.95
- IMMX $3.00
- Technical
- Relative Strength Index (RSI)
- SPCB 55.51
- IMMX 52.67
- Support Level
- SPCB $9.66
- IMMX $2.16
- Resistance Level
- SPCB $11.14
- IMMX $2.46
- Average True Range (ATR)
- SPCB 0.89
- IMMX 0.17
- MACD
- SPCB -0.14
- IMMX -0.02
- Stochastic Oscillator
- SPCB 36.18
- IMMX 27.33
About SPCB SuperCom Ltd. (Israel)
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.